5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | NEUTRAL | NEUTRAL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | N/A | N/A | N/A | 1.09▲ | 1.18▼ |
MA10 | N/A | N/A | N/A | 1.12▲ | 1.18▼ |
MA20 | N/A | N/A | N/A | 1.18▼ | 1.42▼ |
MA50 | N/A | N/A | N/A | 1.18▼ | 3.94▼ |
MA100 | N/A | N/A | N/A | 1.46▼ | 36.08▼ |
MA200 | N/A | N/A | N/A | 2.50▼ | 67.98▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | N/A | N/A | N/A | -0.008▼ | 0.412▲ |
RSI | N/A | N/A | N/A | 42.224▼ | 19.935▼ |
STOCH | N/A | N/A | N/A | 25.535 | 38.587 |
WILL %R | N/A | N/A | N/A | -68.022 | -73.643 |
CCI | N/A | N/A | N/A | -44.792 | -62.297 |
Thursday, March 23, 2023 10:06 AM
GOTHENBURG, SE / ACCESSWIRE / March 23, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL) (FRA:3XV ... Section 8 of the Swedish Companies Act, meaning that the resolution shall be supported by ...
|
Thursday, March 23, 2023 08:20 AM
Royalty Pharma has acquired an interest in PureTech's royalty in Karuna Therapeutics' KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains i ...
|
Thursday, March 23, 2023 07:30 AM
PERTH, AUSTRALIA / ACCESSWIRE / March 23, 2023 / Centamin plc ("Centamin" or "the Company")(LSE:CEY)(TSX:CEE) In accordance with the ... as it forms part of UK domestic law by virtue of the European ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
22/03/23 | 1.125 | 1.1275 | 1.10 | 1.125 | 1,200,177 |
21/03/23 | 1.175 | 1.27 | 1.11 | 1.125 | 4,522,416 |
20/03/23 | 1.075 | 1.075 | 1.075 | 1.075 | 1,340,000 |
17/03/23 | 1.075 | 1.075 | 1.0651 | 1.075 | 91,867 |
16/03/23 | 1.075 | 1.0888 | 1.074 | 1.075 | 308,086 |
15/03/23 | 1.075 | 1.0888 | 1.074 | 1.075 | 308,086 |
14/03/23 | 1.074 | 1.0888 | 1.074 | 1.075 | 308,086 |
13/03/23 | 1.25 | 1.2845 | 1.011 | 1.05 | 3,244,384 |
10/03/23 | 1.25 | 1.25 | 1.225 | 1.25 | 582,670 |
09/03/23 | 1.3125 | 1.3125 | 1.275 | 1.275 | 150,000 |
|
|
||||
|
|
||||
|
|